EMMA insider transaction filings
Emmaus Life Sciences, Inc. — 14 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen EMMA transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 1 Form 4 filing. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 1 filing by 1 insider — 530,767 shares, $18,126 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 94,767 shares @ $0.06 ($5,686) by LEE WILLIS C, filed 2026-09-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| LEE WILLIS C — CEO, Director | 1 | 6 legs · 530,767 sh · $18,126 | — | — |
Recent Form 4 filings — Emmaus Life Sciences, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | LEE WILLIS C — CEO, Director | Purchase (P): 70,000 @ $0.02 · Purchase (P): 170,000 @ $0.01 · Purchase (P): 46,000 @ $0.04 · Purchase (P): 50,000 @ $0.05 · Purchase (P): 94,767 @ $0.06 · Purchase (P): 100,000 @ $0.05 | EDGAR |
| 2024-09-18 | 4 | Lim Seah H. — Director | Purchase (P): 20,000 @ $0.04 | EDGAR |
| 2024-02-29 | 4 | LEE WILLIS C — Co-President & COO, Director | Purchase (P): 13,200 @ $0.12 · Purchase (P): 10,000 @ $0.13 · Purchase (P): 15,000 @ $0.12 · Purchase (P): 77,000 @ $0.13 | EDGAR |
| 2024-02-05 | 4 | Lim Seah H. — Director | Grant/award (A): 100,000 (derivative) @ $0.15 | EDGAR |
| 2024-02-05 | 4 | Stark Charles William — CSO & EVP Clinical Development | Grant/award (A): 200,000 (derivative) @ $0.15 | EDGAR |
| 2024-02-05 | 4 | Sekulich George — Co-President & CCO, Director | Grant/award (A): 200,000 (derivative) @ $0.15 | EDGAR |
| 2024-02-05 | 4 | ZEN Wei Peu — Director | Grant/award (A): 100,000 (derivative) @ $0.15 | EDGAR |
| 2024-02-05 | 4 | Zwicker Ian Harvey — Director | Grant/award (A): 100,000 (derivative) @ $0.15 | EDGAR |
| 2024-02-05 | 4 | NAGASAKI YASUSHI — CFO | Grant/award (A): 200,000 (derivative) @ $0.15 | EDGAR |
| 2024-02-05 | 4 | LEE WILLIS C — Co-President & COO, Director | Grant/award (A): 200,000 (derivative) @ $0.15 | EDGAR |
| 2024-01-03 | 4/A | LEE WILLIS C — COO, Director | Purchase (P): 6,500 @ $0.21 · Purchase (P): 6,000 @ $0.15 · Purchase (P): 1,100 @ $0.12 · Purchase (P): 12,000 @ $0.12 · Purchase (P): 36,000 @ $0.12 · Purchase (P): 59,400 @ $0.12 | EDGAR |
| 2023-12-21 | 4 | Lim Seah H. — Director | Sale (S): 32,500 @ $0.05 | EDGAR |
| 2023-12-19 | 4 | Lim Seah H. — Director | Purchase (P): 25,400 @ $0.11 · Purchase (P): 92,100 @ $0.27 · Purchase (P): 20,000 @ $0.15 · Purchase (P): 1,700 @ $0.15 · Sale (S): 6,000 @ $0.11 · Other (J): 4,447,426 @ $0.29 · +1 more | EDGAR |
| 2023-12-19 | 4 | ZEN Wei Peu — Director | Other (J): 3,760,983 @ $0.29 · Other (J): 2,000,000 (derivative) @ $0.50 | EDGAR |
Recent 8-K events — Emmaus Life Sciences, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-31 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-04 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-31 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EMMA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →